<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnosis of acromegaly</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnosis of acromegaly</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diagnosis of acromegaly</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shlomo Melmed, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laurence Katznelson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 03, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acromegaly results from persistent hypersecretion of growth hormone (GH). Excess GH stimulates hepatic secretion of insulin-like growth factor-1 (IGF-1), which causes most of the clinical manifestations of acromegaly.</p><p>The clinical diagnosis is often delayed because of the slow progression of the signs of acromegaly over a period of many years. GH excess that occurs before fusion of the epiphyseal growth plates in a child or adolescent is called pituitary gigantism and is discussed separately.</p><p>The diagnostic approach to acromegaly will be reviewed here. GH excess in children and adolescents and the causes, clinical manifestations, and treatment of acromegaly are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5855.html" rel="external">"Pituitary gigantism"</a> and  <a class="medical medical_review" href="/z/d/html/6633.html" rel="external">"Causes and clinical manifestations of acromegaly"</a> and  <a class="medical medical_review" href="/z/d/html/6625.html" rel="external">"Treatment of acromegaly"</a>.)</p><p class="headingAnchor" id="H109012597"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Acromegaly has been considered to be a rare disease, with an estimated prevalence in Europe of 30 to 70 individuals per million [<a href="#rid1">1,2</a>]. However, current estimates are considerably higher [<a href="#rid2">2-4</a>]. In one report, seven new cases of acromegaly were identified among 6773 unselected adults in a primary care population who underwent plasma insulin-like growth factor-1 (IGF-1) screening; this suggests a population prevalence as high as 1000 per million individuals [<a href="#rid5">5</a>]. A similar uncontrolled IGF-1 screening study in over 2000 individuals with type 2 diabetes found a prevalence of approximately 480 per million individuals [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H109012735"><span class="h1">WHO SHOULD BE TESTED FOR ACROMEGALY?</span></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of acromegaly should be suspected in individuals who present with the typical clinical features of growth hormone (GH) excess, which include the enlargement during adulthood of the jaw (macrognathia), hands, and feet, which result in increasing shoe and glove size and the need to enlarge finger rings. (See  <a class="medical medical_review" href="/z/d/html/6633.html" rel="external">"Causes and clinical manifestations of acromegaly", section on 'Effects of GH/IGF-1 excess'</a>.)</p><p></p><p class="bulletIndent1">The facial features become coarse, with enlargement of the nose and frontal bones as well as the jaw, and the upper incisors may become spread apart. Despite the prominence of these findings at the time of diagnosis, the rate of change is so slow that few patients seek care because their appearance had changed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other features include cardiovascular disease, sleep apnea, type 2 diabetes, arthropathies, carpal tunnel syndrome, and problems directly related to the pituitary tumor size (headache, visual loss).</p><p></p><p class="bulletIndent1">However, because acromegaly is rare, we suggest against screening patients with isolated sleep apnea, uncontrolled diabetes, arthropathy, or carpal tunnel syndrome (unless there is a clinical suspicion of the disorder).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We do suggest testing in patients who present with a <strong>cluster</strong> of the following conditions, even if they do not have the typical manifestations of acromegaly (eg, acral and facial features) [<a href="#rid7">7</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sleep apnea, uncontrolled diabetes, carpal tunnel syndrome, colon polyps, cardiac failure with hypertension.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Jaw prognathism or new-onset severe snoring or sleep apnea in a person without obesity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pituitary macroadenoma.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The diagnosis should also be considered when a pituitary mass is identified on an imaging study; 75 to 80 percent of somatotroph adenomas are macroadenomas at the time of diagnosis. Some patients may be asymptomatic in spite of raised GH and insulin-like growth factor-1 (IGF-1) levels.</p><p></p><p>In the past, most patients had pituitary adenomas that caused visual field defects, but this is less common now, presumably because of increased awareness of the disease and earlier diagnosis. The percentage of patients with visual defects at presentation is now estimated to be approximately 6 percent, down from 15 to 25 percent in 1975 [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H86308002"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>Once a patient is suspected to have acromegaly, the first step is biochemical testing to confirm the clinical diagnosis, followed by imaging to determine the cause of the excess growth hormone (GH) secretion. (<a class="graphic graphic_algorithm graphicRef71636" href="/z/d/graphic/71636.html" rel="external">algorithm 1</a>)The cause is a somatotroph adenoma of the pituitary in over 95 percent of cases (<a class="graphic graphic_table graphicRef73104" href="/z/d/graphic/73104.html" rel="external">table 1</a>) [<a href="#rid8">8</a>]. (See <a class="local">'Determining the source of excess GH'</a> below.)</p><p class="headingAnchor" id="H239994417"><span class="h2">Biochemical testing</span><span class="headingEndMark"> — </span>The diagnosis of acromegaly is a biochemical one and does <strong>not</strong> require the presence of typical phenotypic features <strong>or</strong> the presence of a pituitary tumor on magnetic resonance imaging (MRI). Therefore, biochemical testing of anyone with a clinical picture suggestive of acromegaly (eg, pituitary tumor of any size or signs and symptoms of acromegaly) is essential. (See <a class="local">'Who should be tested for acromegaly?'</a> above.)</p><p class="headingAnchor" id="H135819880"><span class="h3">Serum IGF-1 concentration</span><span class="headingEndMark"> — </span>The best <strong>single</strong> test for the diagnosis of acromegaly is measurement of serum insulin-like growth factor-1 (IGF-1) (<a class="graphic graphic_algorithm graphicRef71636" href="/z/d/graphic/71636.html" rel="external">algorithm 1</a>) [<a href="#rid7">7,9,10</a>]. Unlike GH, serum IGF-1 concentrations do not vary from hour to hour according to food intake, exercise, or sleep, but instead they reflect integrated GH secretion during the preceding day or longer. Serum IGF-1 concentrations are elevated in virtually all patients with acromegaly and provide excellent discrimination from normal individuals [<a href="#rid11">11,12</a>].</p><p>Our approach, which is similar to that of the Endocrine Society [<a href="#rid7">7</a>], includes measurement of a serum insulin-like growth factor-1 (IGF-1) concentration as the first step (<a class="graphic graphic_algorithm graphicRef71636" href="/z/d/graphic/71636.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>An unequivocally elevated serum IGF-1 concentration in a patient with typical clinical manifestations of acromegaly confirms the diagnosis of acromegaly. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A normal serum IGF-1 concentration is strong evidence that the patient does <strong>not</strong> have acromegaly. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the serum IGF-1 concentration is equivocal, serum GH should be measured after oral glucose administration. Inadequate suppression of GH after a glucose load confirms the diagnosis of acromegaly. (See <a class="local">'Determining the source of excess GH'</a> below.)</p><p></p><p>Both serum GH concentrations and IGF-1 concentrations are increased in virtually all patients with acromegaly. The increase in serum IGF-1 is often disproportionately greater than that in GH for two reasons: GH secretion fluctuates more, and GH stimulates the secretion of IGF-1-binding protein-3 (IGFBP-3), the major IGF-1 binding protein in serum.</p><p>The results must be interpreted, however, according to the patient's age. In normal subjects, serum IGF-1 concentrations are highest during puberty and decline gradually thereafter. Values are significantly lower in adults over the age of 60 years than in younger subjects. Thus, an apparently "normal" value in a patient aged 70 years may in fact be elevated.</p><p>In addition, there are a number of conditions that are associated with lower serum IGF-1 concentrations, including hypothyroidism, malnutrition, poorly controlled type 1 diabetes, liver failure, renal failure, and oral estrogen use. In these situations, it is possible that the diagnosis of acromegaly could be missed, and an oral glucose tolerance test (OGTT) should also be performed if the disorder is suspected [<a href="#rid2">2</a>].</p><p>A further caution is that values from one laboratory may not be comparable with those from another laboratory. A major cause of this finding is a difference in the calibration standards for the assay [<a href="#rid13">13</a>].</p><p>All patients with elevated age-adjusted IGF-1 levels should undergo testing for GH hypersecretion (eg, measurement of serum GH after oral glucose administration).</p><p class="headingAnchor" id="H135819594"><span class="h3">Oral glucose tolerance test</span><span class="headingEndMark"> — </span>The most specific dynamic test for establishing the diagnosis of acromegaly is an OGTT. When performing the test, we measure serum GH before and two hours after glucose administration; the criterion for the diagnosis of acromegaly is a GH concentration greater than 1 ng/mL. In normal subjects, serum GH concentrations fall to 1 ng/mL or less within two hours after ingestion of 75 g glucose. In contrast, the post-glucose values are greater than 2 ng/mL in over 85 percent of patients with acromegaly.</p><p>OGTT is the gold standard for determining control of GH secretion after surgical treatment, but it does not appear to be useful in assessing biochemical control in patients receiving medical therapy with somatostatin analogs. In these patients, both basal and post-glucose GH levels are highly discordant with serum IGF-1 concentrations [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/6625.html" rel="external">"Treatment of acromegaly", section on 'Monitoring'</a>.)</p><p>These results were obtained mainly with a radioimmunoassay method for the measurement of GH. If one of the newer, highly sensitive immunoradiometric or immunochemiluminescent GH assays is used, the serum GH concentration falls to less than 0.3 ng/mL after oral glucose administration in normal subjects [<a href="#rid15">15</a>]. Thus, the diagnosis of acromegaly can be made when the serum GH concentration remains above 1 ng/mL using standard assays. More importantly, these more sensitive assays may give better discrimination between those with and without acromegaly [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H239994480"><span class="h3">Limitations of random serum GH measurements</span><span class="headingEndMark"> — </span>Random serum growth hormone (GH) measurements are not useful for the diagnosis of acromegaly. GH secretion in normal subjects is pulsatile, diurnal, and stimulated by a variety of factors, including short-term fasting, exercise, stress, and sleep; in addition, GH clearance is rapid (plasma half-life of approximately 20 minutes) [<a href="#rid16">16</a>]. As a result, serum GH concentrations fluctuate widely, ranging from less than 0.5 to 1 ng/mL (less than 0.1 ng/mL using very sensitive assays [<a href="#rid17">17</a>]) during most of the day, to 2 to 5 ng/mL before the next meal or after exercise, to as high as 20 or 30 ng/mL at night or after vigorous exercise [<a href="#rid2">2</a>]. Serum GH concentrations also may be high in patients with uncontrolled diabetes mellitus, liver disease, and malnutrition.</p><p>All patients with acromegaly have increased GH secretion. However, the random serum GH concentration is often in the range of 2 to 10 ng/mL during much of the day, values that can be found in normal subjects. Unlike normal subjects, the patient's serum GH concentrations change little during the day or night and, in most patients, do not change in response to stimuli such as food or exercise. Nevertheless, because of the variations in serum GH that occur in normal subjects and in patients with other disorders, a high value cannot be interpreted without knowing when the blood sample was obtained and something about the patient. To obviate these problems, it is best <strong>not</strong> to obtain random measurements of serum GH.</p><p class="headingAnchor" id="H135819600"><span class="h3">Other dynamic tests</span><span class="headingEndMark"> — </span>Although rarely necessary, other dynamic tests can be done. An example of when these might be performed would be a patient in whom acromegaly is suspected clinically but whose IGF-1 and OGTT results are normal.</p><p>Thyrotropin-releasing hormone (TRH), in a dose of 500 mcg intravenously, raises serum GH concentrations by 50 percent or more in approximately one-half of patients with acromegaly, with peak values occurring at 20 to 30 minutes; serum GH does not rise in normal subjects [<a href="#rid18">18</a>]. Conversely, L-DOPA (500 mg orally) reduces serum GH concentrations by 50 percent or more in approximately one-half of patients with acromegaly, while it raises the GH concentration in normal subjects [<a href="#rid2">2</a>]. TRH is unavailable in the United States.</p><p class="headingAnchor" id="H135819606"><span class="h3">Serum IGFBP-3 concentration</span><span class="headingEndMark"> — </span>Because IGF-1-binding protein-3 (IGFBP-3) secretion is GH-dependent (as is IGF-1), serum IGFBP-3 concentrations are elevated in patients with acromegaly [<a href="#rid19">19</a>]. There is, however, considerable overlap of these values with those in normal persons, thereby limiting the utility of this measurement [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Determining the source of excess GH</span></p><p class="headingAnchor" id="H66552454"><span class="h3">Pituitary MRI</span><span class="headingEndMark"> — </span>Once GH hypersecretion has been confirmed, the next step is magnetic resonance imaging (MRI) of the pituitary because a somatotroph adenoma of the pituitary is by far the most common cause of acromegaly (<a class="graphic graphic_table graphicRef73104" href="/z/d/graphic/73104.html" rel="external">table 1</a>). In one report of 39 patients undergoing pituitary MRI for suspected acromegaly, a mass was identified in 27 of the 39 (69 percent) [<a href="#rid21">21</a>].</p><p>Pituitary tumors as small as 2 mm in diameter can be detected with this technique, and the dimensions and anatomic extent of the tumor can be accurately identified (<a class="graphic graphic_diagnosticimage graphicRef63948" href="/z/d/graphic/63948.html" rel="external">image 1</a>); computed tomography is less sensitive. In approximately 75 percent of patients with somatotroph adenomas, the tumor is a macroadenoma (tumor diameter 10 mm or more), and the tumor may extend to the parasellar or suprasellar region. An occasional patient has an empty sella with the tumor situated within the normal pituitary tissue lining the sella turcica.</p><p>It is important to remember that MRI does not distinguish between functioning and nonfunctioning tumors; this distinction must be based upon biochemical studies. This is an important concern because approximately 10 to 20 percent of normal subjects have MRI or autopsy evidence of a pituitary microadenoma. (See  <a class="medical medical_review" href="/z/d/html/6632.html" rel="external">"Causes, presentation, and evaluation of sellar masses"</a>.)</p><p>When no clear mass is seen on a dedicated sella MRI, we consider additional imaging, including chest and abdominal CT scans, and DOTATATE PET scan. However, most of these patients have a somatotroph adenoma, just too small to be detected by routine imaging.</p><p class="headingAnchor" id="H9"><span class="h3">Other studies</span><span class="headingEndMark"> — </span>Other rare causes of acromegaly include pituitary somatotroph carcinoma, a hypothalamic tumor secreting growth hormone-releasing hormone (GHRH), a nonendocrine tumor secreting GHRH, ectopic secretion of GH by a nonendocrine tumor, and excess growth factor activity (acromegaloidism) [<a href="#rid22">22</a>].</p><p>MRI of the head and pituitary should identify some of these other tumors. If the MRI is normal, abdominal and chest imaging should be performed to look for an ectopic source of hormone secretion, followed by catheterization studies in an attempt to demonstrate an arteriovenous gradient of either GH or GHRH in the region of the tumor [<a href="#rid8">8</a>].</p><p>Ectopic GHRH secretion accounts for only 0.5 percent of cases of acromegaly [<a href="#rid22">22</a>]. Serum GHRH is the only specific marker for this disorder, and concentrations are usually quite elevated; special arrangements with a reliable laboratory must be made for this assay. Pituitary MRI often reveals a normal-sized or enlarged gland, but other patients appear to have an adenoma. GHRH should not be measured routinely but should be if a clear-cut pituitary adenoma is not seen on MRI or postoperatively if histologic and immunocytochemical examination of the excised pituitary tissue reveals somatotroph hyperplasia rather than a somatotroph adenoma.</p><p class="headingAnchor" id="H4195321803"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116763.html" rel="external">"Society guideline links: Diagnosis and treatment of acromegaly"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16728.html" rel="external">"Patient education: Acromegaly (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2166.html" rel="external">"Patient education: Acromegaly (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H11"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Acromegaly has been considered to be a rare disease, with an estimated prevalence in Europe of 30 to 70 individuals per million [<a href="#rid1">1,2</a>]. However, current prevalence estimates are considerably higher. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of acromegaly should be suspected in individuals who present with the typical clinical features of growth hormone (GH) excess, which include an enlarged jaw (macrognathia) and enlarged hands and feet, which result in increasing shoe and glove size and the need to enlarge rings. The facial features become coarse, with enlargement of the nose and frontal bones as well as the jaw, and the teeth become spread apart.</p><p></p><p class="bulletIndent1">We also suggest testing in patients who present with a <strong>cluster</strong> of the following conditions, even if they do not have the typical manifestations of acromegaly (eg, acral and facial features): sleep apnea, uncontrolled diabetes, carpal tunnel syndrome, colon polyps, and cardiac failure with hypertension. (See <a class="local">'Who should be tested for acromegaly?'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis should also be considered when a pituitary mass is identified on an imaging study; 75 to 80 percent of somatotroph adenomas are macroadenomas at the time of diagnosis. (See <a class="local">'Who should be tested for acromegaly?'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The first step in the diagnosis is measurement of a serum insulin-like growth factor-1 (IGF-1) concentration (<a class="graphic graphic_algorithm graphicRef71636" href="/z/d/graphic/71636.html" rel="external">algorithm 1</a>). An unequivocally elevated serum IGF-1 concentration in a patient with typical clinical manifestations of acromegaly confirms the diagnosis of acromegaly. A normal serum IGF-1 concentration is strong evidence that the patient does <strong>not</strong> have acromegaly. </p><p></p><p class="bulletIndent1">If the serum IGF-1 concentration is equivocal, serum GH should be measured after oral glucose administration. Inadequate suppression of serum GH after a glucose load confirms the diagnosis of acromegaly. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Once the biochemical diagnosis is made, pituitary magnetic resonance imaging (MRI) should be performed (<a class="graphic graphic_algorithm graphicRef71636" href="/z/d/graphic/71636.html" rel="external">algorithm 1</a>); a pituitary adenoma is found in the majority of cases. If the MRI is normal, then studies to identify a growth hormone-releasing hormone (GHRH)- or GH-secreting tumor should be undertaken. (See <a class="local">'Other studies'</a> above and <a class="local">'Pituitary MRI'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bengtsson BA, Edén S, Ernest I, et al. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988; 223:327.</a></li><li><a class="nounderline abstract_t">Ribeiro-Oliveira A Jr, Barkan A. The changing face of acromegaly--advances in diagnosis and treatment. Nat Rev Endocrinol 2012; 8:605.</a></li><li><a class="nounderline abstract_t">Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010; 72:377.</a></li><li><a class="nounderline abstract_t">Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006; 91:4769.</a></li><li><a class="nounderline abstract_t">Schneider HJ, Sievers C, Saller B, et al. High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin Endocrinol (Oxf) 2008; 69:432.</a></li><li><a class="nounderline abstract_t">Rosario PW. Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population. Pituitary 2011; 14:217.</a></li><li><a class="nounderline abstract_t">Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99:3933.</a></li><li><a class="nounderline abstract_t">Melmed S. Medical progress: Acromegaly. N Engl J Med 2006; 355:2558.</a></li><li><a class="nounderline abstract_t">Kannan S, Kennedy L. Diagnosis of acromegaly: state of the art. Expert Opin Med Diagn 2013; 7:443.</a></li><li><a class="nounderline abstract_t">Akirov A, Masri-Iraqi H, Dotan I, Shimon I. The Biochemical Diagnosis of Acromegaly. J Clin Med 2021; 10.</a></li><li><a class="nounderline abstract_t">Clemmons DR, Van Wyk JJ, Ridgway EC, et al. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 1979; 301:1138.</a></li><li><a class="nounderline abstract_t">Stoffel-Wagner B, Springer W, Bidlingmaier F, Klingmüller D. A comparison of different methods for diagnosing acromegaly. Clin Endocrinol (Oxf) 1997; 46:531.</a></li><li><a class="nounderline abstract_t">Clemmons DR. Clinical utility of measurements of insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2006; 2:436.</a></li><li><a class="nounderline abstract_t">Carmichael JD, Bonert VS, Mirocha JM, Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 2009; 94:523.</a></li><li><a class="nounderline abstract_t">Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998; 83:3808.</a></li><li><a class="nounderline abstract_t">Iranmanesh A, Grisso B, Veldhuis JD. Low basal and persistent pulsatile growth hormone secretion are revealed in normal and hyposomatotropic men studied with a new ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab 1994; 78:526.</a></li><li><a class="nounderline abstract_t">Chapman IM, Hartman ML, Straume M, et al. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. J Clin Endocrinol Metab 1994; 78:1312.</a></li><li><a class="nounderline abstract_t">Irie M, Tsushima T. Increase of serum growth hormone concentration following thyrotropin-releasing hormone injection in patients with acromegaly or gigantism. J Clin Endocrinol Metab 1972; 35:97.</a></li><li><a class="nounderline abstract_t">Grinspoon S, Clemmons D, Swearingen B, Klibanski A. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. J Clin Endocrinol Metab 1995; 80:927.</a></li><li><a class="nounderline abstract_t">Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009; 94:1509.</a></li><li><a class="nounderline abstract_t">Famini P, Maya MM, Melmed S. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab 2011; 96:1633.</a></li><li><a class="nounderline abstract_t">Garby L, Caron P, Claustrat F, et al. Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing hormone (GHRH): a French nationwide series of 21 cases. J Clin Endocrinol Metab 2012; 97:2093.</a></li></ol></div><div id="topicVersionRevision">Topic 6635 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3369313" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22733271" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The changing face of acromegaly--advances in diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19650784" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16968795" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18284644" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21170595" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25356808" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acromegaly: an endocrine society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17167139" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Medical progress: Acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23971897" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Diagnosis of acromegaly: state of the art.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33803429" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The Biochemical Diagnosis of Acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/492275" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Evaluation of acromegaly by radioimmunoassay of somatomedin-C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9231047" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A comparison of different methods for diagnosing acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16932333" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical utility of measurements of insulin-like growth factor 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19033371" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9814451" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8126122" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Low basal and persistent pulsatile growth hormone secretion are revealed in normal and hyposomatotropic men studied with a new ultrasensitive chemiluminescence assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8200931" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4624350" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Increase of serum growth hormone concentration following thyrotropin-releasing hormone injection in patients with acromegaly or gigantism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7533774" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19208732" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Guidelines for acromegaly management: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21470998" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22442262" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing hormone (GHRH): a French nationwide series of 21 cases.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
